Even as weight-loss drugs such as Wegovy and Zepbound explode in popularity, many Americans struggle to afford them.

The proposal would expand coverage of anti-obesity drugs to 7.5 million people covered by Medicare and Medicaid, the Biden ...

People taking new weight-loss drugs say they curb cravings for booze, drugs, and nicotine. Did scientists inadvertently ...

There has been a lot of conversation lately about if new weight loss drugs like Wegovy and Mounjaro should be covered by ...

Suffolk County employees and beneficiaries hoping to shed pounds using the latest weight-loss ... drugs, increased more than $3 million over two years, from $1.2 million in the second quarter of ...

The high list prices of these new weight loss drugs are costly for ... have been in short supply since 2022, but the FDA declared on Oct. 2 the drugs were no longer in shortage.

They've been dubbed 'game-changers' in the world of obesity, making the seemingly impossible, possible - significant weight ...

Ozempic — or any of the GLP-1 class of diet drugs that includes Wegovy and Mounjaro — hasn’t just changed our nation’s ...

Pharmaceutical giants Eli Lilly and Company & Novo Nordisk A/S face challenges in the obesity market despite promising data.

Millions of obese Americans would be eligible to have popular weight-loss drugs like Wegovy or Ozempic covered by Medicare or ...

Civello helped negotiate the new insurance rules for GLP-1 semaglutide weight loss drugs. Beginning January ... In the Second quarter of 2022, it spent $1.2 million on GLP-1s.